Establishment of Vaccine Business Division

Huons, a subsidiary of Huons Group, is entering the vaccine market in partnership with Sanofi Korea, the Korean branch of the global biopharmaceutical company Sanofi.


On March 25, Huons signed a contract at its headquarters in Pangyo, Seongnam, Gyeonggi Province, with Sanofi for domestic distribution and co-promotion (joint sales and marketing) of five types of injectable vaccines.

Huons signed a distribution contract for five types of vaccines with Sanofi on the 25th at the Huons Group headquarters in Pangyo, Seongnam. Soo-young Song, CEO of Huons (left), and Heekyung Park, Head of Vaccine Business Division at Sanofi Korea (right), are taking a commemorative photo. Photo by Huons

Huons signed a distribution contract for five types of vaccines with Sanofi on the 25th at the Huons Group headquarters in Pangyo, Seongnam. Soo-young Song, CEO of Huons (left), and Heekyung Park, Head of Vaccine Business Division at Sanofi Korea (right), are taking a commemorative photo. Photo by Huons

View original image

Through this agreement, starting April 1, Huons will be responsible for the domestic distribution and promotion of a total of five vaccines: the influenza vaccines “Vaxigrip” (standard-dose) and “Efluelda” (high-dose); and, for adult immunization, the diphtheria/tetanus/pertussis vaccine “Adacel,” the hepatitis A vaccine “Avaxim160,” and the meningococcal vaccine “MenQuadfi.”


Sanofi is a global biopharmaceutical company that accelerates innovation through research and development (R&D) and artificial intelligence (AI), supplying medicines and vaccines that treat and protect millions of people worldwide. Huons possesses expertise in injectable sales and cold chain logistics in Korea. Both companies expect that their respective strengths will create synergy in targeting the domestic vaccine market.


Recently, Huons established a dedicated Vaccine Business Division to systematically promote its vaccine business. By leveraging its experienced sales professionals and existing customer network, the company plans to offer world-class vaccine accessibility to healthcare professionals and patients in Korea.


In particular, Huons aims to utilize its cold chain management technology and logistics infrastructure, developed through experience in distributing refrigerated injectables such as “Merit C Injection” and “Hudaxin Injection,” to reliably deliver temperature- and sensitivity-critical vaccines to medical institutions nationwide.


Soo-Young Song, CEO of Huons, stated, “Collaboration with Sanofi, a company recognized for its scientific credibility and quality in the global vaccine field, will be an important turning point for Huons to grow as a global public health partner. By combining Sanofi’s innovative solutions with Huons’ expertise in pharmaceutical sales, we will set new standards in the domestic vaccine market.”



Meanwhile, Huons plans to use its strategic partnerships with multinational pharmaceutical companies as a new growth engine for its vaccine business, expanding its pipeline and strengthening sustainable growth drivers.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing